Global Antiviral Immunoglobulin Market Strategic Research Report

Scope of the Report

The global Antiviral Immunoglobulin market size is predicted to grow from US$ 11,011 million in 2025 to US$ 17,428 million in 2032; it is expected to grow at a CAGR of 6.8% from 2026 to 2032.

Antiviral immunoglobulin refers to a class of biological medicinal products containing specific antibodies used for the prevention (prophylaxis) or treatment of viral diseases, operating on the principle of passive immunization. In 2025,global antiviral immunoglobulin production reached approximately 1,731K Kg, with an average global market price of around USD 6,500 per Kg. A factory gross profit of USD 1,950 per Kg with 30% gross margin. A single line full machine capacity production is around 25K Kg per line per year.The upstream segment is highly dependent on the global human plasma supply chain. Downstream demand is concentrated in hospitals,emergency care and research and specialty clinics. A hepatitis B-positive liver transplant recipient receives HBIG therapy following transplantation to reduce the risk of viral recurrence and graft failure. China isleading due to aggressive expansion of plasma-derived biologics manufacturing, increasing healthcare expenditure, and growing domestic demand for immunotherapy products. while US following due to advanced transplant medicine, high immunoglobulin utilization rates, strong reimbursement systems, and continuous expansion of plasma donation infrastructure.

Global key Antiviral Immunoglobulin players cover ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Antiviral Immunoglobulin market?

What factors are driving Antiviral Immunoglobulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Antiviral Immunoglobulin market opportunities vary by end market size?

How does Antiviral Immunoglobulin break out by Type, by Application?

This report presents a comprehensive overview of the global Antiviral Immunoglobulin market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Human Plasma Derived Polyclonal
• Hyperimmune Specific Globulin
• Recombinant Monoclonal Antibody (mAb)
• Animal Derived (Equine/Ovine)
• Others

Segment by IgG Purity

• Standard Fractionated Grade (90%–95%)
• Clinical High Purity Grade (96%–98%)
• Ultra Purified Specialty Grade(99%)

Segment by Therapeutic Area

• Transplantation
• Infectious Disease Prophylaxis
• Immunodeficiency
• Neurology (Autoimmune)
• Others

Segment by Application

• Hospitals
• Specialty Clinics
• Home Care
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Antiviral Immunoglobulin market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Specialty Clinics, Home Care evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact